Treatment of Social and Language Deficits With Leucovorin for Young Children With Autism

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The primary objective of this study is to evaluate the cognitive and behavioral effects of liquid leucovorin calcium on young children with autism spectrum disorder (ASD) and determine whether it improves social communication as well as the core and associated symptoms of ASD. The investigators will enroll 80 children across two sites, between the ages of 2.5 and 5 years, with confirmed ASD and known social and communication delays. Participation will last approximately 26 weeks, from screening visit to end of treatment.
Epistemonikos ID: afe6915d0aa6f59c167c72571d95bd02c9c9a171
First added on: May 22, 2024